跳至主要内容
临床试验/NCT02586168
NCT02586168已完成2 期

The Effect of Gemcabene (CI-1027) on Insulin Sensitivity in Nondiabetic Subjects

NeuroBo Pharmaceuticals Inc.0 个研究点目标入组 53 人开始时间: 2001年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
53
主要终点
Insulin sensitivity

研究概览

简要总结

The purpose of this study is to determine the effect of gemcabene on insulin sensitivity as defined by average glucose disposal rate.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Good health, as determined by medical history, physical examination, EKG and clinical laboratory assessments
  • Males; and females of non-reproductive potential
  • Non-diabetic

排除标准

  • Use of any medication considered unacceptable by the clinical investigators during the 14-day period before the start of Day
  • Hormone Replacement Therapy is acceptable.
  • Use of a lipid-lowering agent (niacin, fibrates, statin) during the 8 weeks before screening
  • Use of any anti-diabetic medications
  • Use of any steroid medications
  • Donation of any blood or plasma product or participation in another study in the 30 days prior to Day 1
  • If female, pregnant, lactating or of childbearing potential; and
  • History of significant reaction to any fibrate lipid-lowering agent

研究组 & 干预措施

Gemcabene 900 mg

Experimental

Gemcabene 900 mg

干预措施: Gemcabene 900 mg (Drug)

Placebo

Placebo Comparator

Placebo

干预措施: Placebo (Drug)

结局指标

主要结局

Insulin sensitivity

时间窗: 4 weeks

次要结局

  • Clinical Laboratory - hematology, chemistry(4 weeks)
  • Adverse Events(4 weeks)
  • ECG(4 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

The Effect of Gemcabene on Insulin Sensitivity in... | 临床试验